Atara Biotherapeutics (ATRA) EBITDA Margin (2022 - 2026)
Atara Biotherapeutics (ATRA) reported EBITDA Margin of 803.49% for Q1 2026, down 84221.0% on a YoY basis from N/an in Q1 2025, and down 276.16% quarter-over-quarter from 213.61% in Q4 2025.
Atara Biotherapeutics (ATRA) EBITDA Margin (2022 - 2026) Analysis & Trends
Atara Biotherapeutics has reported EBITDA Margin for 5 years, with the latest figure at 803.49% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 84221.0% year-over-year to 803.49%; the trailing twelve-month figure through Mar 2026 stood at 40.91% (down 3311.0% YoY), and the FY2025 full-year result was 27.06%, up 9313.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 803.49%, down from 213.61% in the prior quarter.
- The five-year high for EBITDA Margin was 38.72% in Q1 2025, with the low at 33339.37% in Q4 2022.
- Historically, EBITDA Margin has averaged 3458.4% across 5 years, with a median of 169.08% in 2025.
- The largest YoY upside for EBITDA Margin was 3210715 bps in 2023 against a maximum downside of 896302 bps in 2023.
- Atara Biotherapeutics' EBITDA Margin stood at 33339.37% in 2022, then soared by 96 bps to 1232.22% in 2023, then soared by 97 bps to 38.8% in 2024, then slumped by 451 bps to 213.61% in 2025, then slumped by 276 bps to 803.49% in 2026.
- The last three EBITDA Margin figures came in at 803.49% (Q1 2026), 213.61% (Q4 2025), and 124.56% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Atara Biotherapeutics | 134.61 Mn | 126.21 Mn | 392,000.00 | -803.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -803.49% |
| Dec 31, 2025 | -213.61% |
| Sep 30, 2025 | -124.56% |
| Jun 30, 2025 | 13.58% |
| Mar 31, 2025 | 38.72% |
| Dec 31, 2024 | -38.80% |
| Sep 30, 2024 | -54.42% |
| Jun 30, 2024 | -66.37% |
| Mar 31, 2024 | -115.52% |
| Dec 31, 2023 | -1,232.22% |
| Sep 30, 2023 | -3,247.66% |
| Jun 30, 2023 | -8,928.63% |
| Mar 31, 2023 | -6,031.08% |
| Dec 31, 2022 | -33,339.37% |
| Jun 30, 2022 | 34.39% |
| Mar 31, 2022 | -1,225.44% |